Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial

Background: SAR341402 (SAR-Asp) is a biosimilar/follow-on of the originator insulin aspart-NovoLog(®)/NovoRapid(®) (NN-Asp). This study investigated whether the efficacy, safety, and immunogenicity findings for SAR-Asp versus NN-Asp, observed over 6 months in people with type 1 (n = 497) or type 2 d...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Diabetes Technol Ther
Prif Awduron: Garg, Satish K., Wernicke-Panten, Karin, Wardecki, Marek, Kramer, Daniel, Delalande, Francois, Franek, Edward, Sadeharju, Karita, Monchamp, Travis, Miossec, Patrick, Mukherjee, Bhaswati, Shah, Viral N.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Mary Ann Liebert, Inc., publishers 2020
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7336880/
https://ncbi.nlm.nih.gov/pubmed/32068436
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/dia.2020.0008
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg